Keiser J, Utzinger J (April 2008). "Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis". JAMA. 299 (16): 1937–48. doi:10.1001/jama.299.16.1937. PMID18430913.
Harder A (March 2002). "Chemotherapeutic approaches to nematodes: current knowledge and outlook". Parasitology Research. 88 (3): 272–277. doi:10.1007/s00436-001-0535-x. PMID11954915.
Waghorn TS, Leathwick DM, Rhodes AP, Lawrence KE, Jackson R, Pomroy WE, et al. (December 2006). "Prevalence of anthelmintic resistance on sheep farms in New Zealand". New Zealand Veterinary Journal. 54 (6): 271–277. doi:10.1080/00480169.2006.36710. PMID17151724.
Nari A, Salles J, Gil A, Waller PJ, Hansen JW (April 1996). "The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: Uruguay". Veterinary Parasitology. 62 (3–4): 213–222. doi:10.1016/0304-4017(95)00908-6. PMID8686167.
Maciel S, Giménez AM, Gaona C, Waller PJ, Hansen JW (April 1996). "The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: Paraguay". Veterinary Parasitology. 62 (3–4): 207–212. doi:10.1016/0304-4017(95)00907-8. PMID8686166.
Echevarria F, Borba MF, Pinheiro AC, Waller PJ, Hansen JW (April 1996). "The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: Brazil". Veterinary Parasitology. 62 (3–4): 199–206. doi:10.1016/0304-4017(95)00906-x. PMID8686165.
Chang A, Osterloh J, Thomas J (September 2010). "Levamisole: a dangerous new cocaine adulterant". Clinical Pharmacology and Therapeutics. 88 (3): 408–11. doi:10.1038/clpt.2010.156. PMID20668440. S2CID31414939.
Kouassi E, Caillé G, Léry L, Larivière L, Vézina M (1986). "Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine". Biopharmaceutics & Drug Disposition. 7 (1): 71–89. doi:10.1002/bdd.2510070110. PMID3754161.
Luyckx M, Rousseau F, Cazin M, Brunet C, Cazin JC, Haguenoer JM, et al. (1982). "Pharmacokinetics of levamisole in healthy subjects and cancer patients". European Journal of Drug Metabolism and Pharmacokinetics. 7 (4): 247–54. doi:10.1007/bf03189626. PMID7166176. S2CID13206196.
Bertol E, Mari F, Milia MG, Politi L, Furlanetto S, Karch SB (July 2011). "Determination of aminorex in human urine samples by GC-MS after use of levamisole". Journal of Pharmaceutical and Biomedical Analysis. 55 (5): 1186–1189. doi:10.1016/j.jpba.2011.03.039. PMID21531521.
Hess C, Ritke N, Broecker S, Madea B, Musshoff F (May 2013). "Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS". Analytical and Bioanalytical Chemistry. 405 (12): 4077–4088. doi:10.1007/s00216-013-6829-x. PMID23436169. S2CID2222462.
Vandamme TF, Demoustier M, Rollmann B (1995). "Quantitation of levamisole in plasma using high performance liquid chromatography". European Journal of Drug Metabolism and Pharmacokinetics. 20 (2): 145–9. doi:10.1007/bf03226369. PMID8582440. S2CID9258640.
Zhu NY, Legatt DF, Turner AR (February 2009). "Agranulocytosis after consumption of cocaine adulterated with levamisole". Annals of Internal Medicine. 150 (4): 287–289. doi:10.7326/0003-4819-150-4-200902170-00102. PMID19153405.
Couderc A, Bérard E, Guigonis V, Vrillon I, Hogan J, Audard V, et al. (December 2017). "[Treatments of steroid-dependent nephrotic syndrome in children]". Archives de Pédiatrie. 24 (12): 1312–1320. doi:10.1016/j.arcped.2017.09.002. PMID29146214.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Keiser J, Utzinger J (April 2008). "Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis". JAMA. 299 (16): 1937–48. doi:10.1001/jama.299.16.1937. PMID18430913.
Harder A (March 2002). "Chemotherapeutic approaches to nematodes: current knowledge and outlook". Parasitology Research. 88 (3): 272–277. doi:10.1007/s00436-001-0535-x. PMID11954915.
Waghorn TS, Leathwick DM, Rhodes AP, Lawrence KE, Jackson R, Pomroy WE, et al. (December 2006). "Prevalence of anthelmintic resistance on sheep farms in New Zealand". New Zealand Veterinary Journal. 54 (6): 271–277. doi:10.1080/00480169.2006.36710. PMID17151724.
Nari A, Salles J, Gil A, Waller PJ, Hansen JW (April 1996). "The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: Uruguay". Veterinary Parasitology. 62 (3–4): 213–222. doi:10.1016/0304-4017(95)00908-6. PMID8686167.
Maciel S, Giménez AM, Gaona C, Waller PJ, Hansen JW (April 1996). "The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: Paraguay". Veterinary Parasitology. 62 (3–4): 207–212. doi:10.1016/0304-4017(95)00907-8. PMID8686166.
Echevarria F, Borba MF, Pinheiro AC, Waller PJ, Hansen JW (April 1996). "The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: Brazil". Veterinary Parasitology. 62 (3–4): 199–206. doi:10.1016/0304-4017(95)00906-x. PMID8686165.
Chang A, Osterloh J, Thomas J (September 2010). "Levamisole: a dangerous new cocaine adulterant". Clinical Pharmacology and Therapeutics. 88 (3): 408–11. doi:10.1038/clpt.2010.156. PMID20668440. S2CID31414939.
Kouassi E, Caillé G, Léry L, Larivière L, Vézina M (1986). "Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine". Biopharmaceutics & Drug Disposition. 7 (1): 71–89. doi:10.1002/bdd.2510070110. PMID3754161.
Luyckx M, Rousseau F, Cazin M, Brunet C, Cazin JC, Haguenoer JM, et al. (1982). "Pharmacokinetics of levamisole in healthy subjects and cancer patients". European Journal of Drug Metabolism and Pharmacokinetics. 7 (4): 247–54. doi:10.1007/bf03189626. PMID7166176. S2CID13206196.
Bertol E, Mari F, Milia MG, Politi L, Furlanetto S, Karch SB (July 2011). "Determination of aminorex in human urine samples by GC-MS after use of levamisole". Journal of Pharmaceutical and Biomedical Analysis. 55 (5): 1186–1189. doi:10.1016/j.jpba.2011.03.039. PMID21531521.
Hess C, Ritke N, Broecker S, Madea B, Musshoff F (May 2013). "Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS". Analytical and Bioanalytical Chemistry. 405 (12): 4077–4088. doi:10.1007/s00216-013-6829-x. PMID23436169. S2CID2222462.
Vandamme TF, Demoustier M, Rollmann B (1995). "Quantitation of levamisole in plasma using high performance liquid chromatography". European Journal of Drug Metabolism and Pharmacokinetics. 20 (2): 145–9. doi:10.1007/bf03226369. PMID8582440. S2CID9258640.
Zhu NY, Legatt DF, Turner AR (February 2009). "Agranulocytosis after consumption of cocaine adulterated with levamisole". Annals of Internal Medicine. 150 (4): 287–289. doi:10.7326/0003-4819-150-4-200902170-00102. PMID19153405.
Couderc A, Bérard E, Guigonis V, Vrillon I, Hogan J, Audard V, et al. (December 2017). "[Treatments of steroid-dependent nephrotic syndrome in children]". Archives de Pédiatrie. 24 (12): 1312–1320. doi:10.1016/j.arcped.2017.09.002. PMID29146214.
Chang A, Osterloh J, Thomas J (September 2010). "Levamisole: a dangerous new cocaine adulterant". Clinical Pharmacology and Therapeutics. 88 (3): 408–11. doi:10.1038/clpt.2010.156. PMID20668440. S2CID31414939.
Luyckx M, Rousseau F, Cazin M, Brunet C, Cazin JC, Haguenoer JM, et al. (1982). "Pharmacokinetics of levamisole in healthy subjects and cancer patients". European Journal of Drug Metabolism and Pharmacokinetics. 7 (4): 247–54. doi:10.1007/bf03189626. PMID7166176. S2CID13206196.
Hess C, Ritke N, Broecker S, Madea B, Musshoff F (May 2013). "Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS". Analytical and Bioanalytical Chemistry. 405 (12): 4077–4088. doi:10.1007/s00216-013-6829-x. PMID23436169. S2CID2222462.
Vandamme TF, Demoustier M, Rollmann B (1995). "Quantitation of levamisole in plasma using high performance liquid chromatography". European Journal of Drug Metabolism and Pharmacokinetics. 20 (2): 145–9. doi:10.1007/bf03226369. PMID8582440. S2CID9258640.
Menni S, Pistritto G, Gianotti R, Ghio L, Edefonti A (1997). "Ear lobe bilateral necrosis by levamisole-induced occlusive vasculitis in a pediatric patient". Pediatric Dermatology. 14 (6): 477–479. doi:10.1111/j.1525-1470.1997.tb00695.x. PMID9436850. S2CID26527277.
Symoens J, DeCree J, Bever WV, Janssen PA (1979). "Levamisole". In Goldberg ME (ed.). Pharmacological and Biochemical Properties of Drug Substances. Vol. 2. Washington: American Pharmaceutical Association. pp. 407–464. OCLC1106595378.